Immunology Department, LHUB-ULB, Université libre de Bruxelles, Brussels, Belgium.
National Influenza Centre, Sciensano, Brussels, Belgium.
PLoS One. 2019 Oct 10;14(10):e0223991. doi: 10.1371/journal.pone.0223991. eCollection 2019.
Patients suffering from Sickle Cell Disease (SCD) are at increased risk for complications due to influenza virus. Annual influenza vaccination is strongly recommended but few clinical studies have assessed its immunogenicity in individuals with SCD. The aim of this study was to explore the biological efficacy of annual influenza vaccination in SCD patients by characterizing both their humoral and cell-mediated immunity against influenza antigen. We also aimed to investigate these immunological responses among SCD individuals according to their treatment (hydroxyurea (HU), chronic blood transfusions (CT), both HU and CT or none of them).
Seventy-two SCD patients (49 receiving HU, 9 on CT, 7 with both and 7 without treatment) and 30 healthy controls were included in the study. All subjects received the tetravalent influenza α-RIX-Tetra® vaccine from the 2016-2017 or 2017-2018 season.
Protective anti-influenza HAI titers were obtained for the majority of SCD patients one month after vaccination but seroconversion rates in patient groups were strongly decreased compared to controls. Immune cell counts, particularly cellular memory including memory T and memory B cells, were greatly reduced in SCD individuals. Functional activation assays confirmed a poorer CD8+ T cell memory. We also document an imbalance of cytokines after influenza vaccination in SCD individuals with an INFγ/IL-10 ratio (Th1-type/Treg-type response) significantly lower in the SCD cohort.
SCD patients undergoing CT showed altered immune regulation as compared to other treatment subgroups. Altogether, the cytokine imbalance, the high regulatory T cell levels and the low memory lymphocyte subset levels observed in the SCD cohort, namely for those on CT, suggest a poor ability of SCD patients to fight against influenza infection. Nevertheless, our serological data support current clinical practice for annual influenza vaccination, though immunogenicity to other vaccines involving immunological memory might be hampered in SCD patients and should be further investigated.
患有镰状细胞病(SCD)的患者因流感病毒而出现并发症的风险增加。强烈建议每年接种流感疫苗,但很少有临床研究评估其在 SCD 患者中的免疫原性。本研究的目的是通过描述 SCD 患者对流感抗原的体液和细胞介导免疫来探索年度流感疫苗接种的生物学效果。我们还旨在根据 SCD 个体的治疗(羟基脲(HU),慢性输血(CT),HU 和 CT 两者或均无)来研究这些免疫反应。
纳入了 72 名 SCD 患者(49 名接受 HU,9 名接受 CT,7 名同时接受 HU 和 CT,7 名未接受治疗)和 30 名健康对照者。所有受试者均接受了 2016-2017 年或 2017-2018 年季节的四价流感 α-RIX-Tetra®疫苗。
大多数 SCD 患者在接种疫苗后一个月获得了保护性抗流感血凝抑制(HAI)滴度,但与对照组相比,患者组的血清转化率大大降低。SCD 个体的免疫细胞计数,特别是包括记忆 T 细胞和记忆 B 细胞在内的细胞记忆,大大减少。功能激活测定证实 CD8+T 细胞记忆较差。我们还记录了 SCD 个体在流感疫苗接种后的细胞因子失衡,SCD 队列中 IFNγ/IL-10 比值(Th1 型/Treg 型反应)明显降低。
与其他治疗亚组相比,接受 CT 的 SCD 患者表现出免疫调节异常。总之,SCD 队列中观察到的细胞因子失衡,高调节性 T 细胞水平和记忆性淋巴细胞亚群水平低,尤其是接受 CT 的患者,表明 SCD 患者对抗流感感染的能力较差。然而,我们的血清学数据支持目前对年度流感疫苗接种的临床实践,尽管涉及免疫记忆的其他疫苗的免疫原性可能在 SCD 患者中受到阻碍,需要进一步研究。